← Oncology Approval Tracker

FDA DECISION ·

Tabrecta

capmatinib · Novartis

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Aug 10, 2022

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic non-small cell lung cancer and a mutation causing MET exon 14 skipping, identified by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

Created a biomarker-directed option for this molecular subgroup under accelerated approval.

What research teams should watch

Confirm the assay can identify the relevant splice alteration and document how a negative plasma result is resolved.

PRIMARY RECORDS

Sources